Search

Displaying results 4781 - 4790 of 7600 in total
  1. Drug

    Anlotinib

    go.drugbank.com/drugs/DB11885
    Investigational

    Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

  2. Drug

    Aclerastide

    go.drugbank.com/drugs/DB12631
    Investigational

    Aclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.

  3. Drug

    Lexanersen

    go.drugbank.com/drugs/DB17933
    Investigational

    Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.

  4. Drug

    RTL-1000

    go.drugbank.com/drugs/DB17946
    Investigational

    RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.

  5. Drug

    PARPI F-18

    go.drugbank.com/drugs/DB18657
    Experimental

    PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.

  6. Drug

    Canvuparatide

    go.drugbank.com/drugs/DB18658
    Investigational

    Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]

  7. Drug

    Ivonescimab

    go.drugbank.com/drugs/DB18931
    Investigational

    Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).

  8. Drug

    Lactide, L-

    go.drugbank.com/drugs/DB19115
    Investigational

    Lactide, L- is under investigation in clinical trial NCT05450471 (Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis).

  9. Drug

    NSI-189

    go.drugbank.com/drugs/DB16230
    Investigational

    NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).

  10. Drug

    KB109

    go.drugbank.com/drugs/DB16531
    Experimental

    KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.